Salvia BioElectronics raises $60M Series B for chronic migraine neuromodulation therapy
Summary
Salvia BioElectronics has completed a $60 million (€53 million) Series B financing round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors including Inkef, Panakès Partners, and SHS Capital. The Dutch company is pioneering MySalvia Therapy, a personalized minimally invasive neuromodulation therapy designed for people with chronic migraine, currently being evaluated in the RECLAIM study.
Why it matters
Migraine is one of the leading causes of disability worldwide, resulting in an estimated $110 billion annually in lost productivity and medical costs in the EU and US alone. The majority of chronic patients discontinue medication within the first year. Salvia's FDA-designated Breakthrough Device offers a promising alternative with an ultra-thin implant that targets key nerves involved in migraine, reducing surgical complexity and recovery time.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial